
What happened
INVO Fertility, Inc. (NASDAQ: IVF) lifted clinic revenue 28% to $2.21 million from $1.72 million in the third quarter. That is $485,364 more than a year earlier.
Total revenue rose 26% to $2.22 million from $1.76 million. Net loss narrowed to $2.1 million from $3.4 million.
For holders, the clinics are still adding sales while losses shrink. The company is not yet profitable as a whole.
INVO Fertility has four operating fertility clinics in the United States. It plans to build, acquire and run fertility clinics and related businesses and technologies. It also still sells INVOcell to third-party clinics.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Revenue | $2.22 million | from $1.76 million, +26% | Consolidated statements of operations |
| Clinic revenue | $2.21 million | from $1.72 million, +28% | Consolidated statements of operations |
| Net loss | $2.1 million | from $3.4 million, -$1.3 million | Consolidated statements of operations |
| Clinic-Level Adjusted EBITDA | $292,114 | from $243,120, +20.1% | Press release non-GAAP discussion |
| Cash | $3.70 million | from $2.08 million, +$1.62 million | Consolidated balance sheets |
| Current liabilities | $4.46 million | from $10.33 million, -$5.87 million | Consolidated balance sheets |
Read more: INVO Fertility (IVF) company research
Why it matters
Loss from operations improved to $1.5 million from $1.6 million. Consolidated Adjusted EBITDA was a loss of $1.0 million, versus a loss of $0.9 million a year earlier.
Corporate overhead still kept consolidated Adjusted EBITDA negative.
Clinic-Level Adjusted EBITDA stayed positive for the seventh straight quarter at $292,114, up from $243,120.
That clinic profit has to cover corporate costs before the company can turn a consolidated profit. It does not yet.
The company said the planned Birmingham acquisition transition cut clinic-level contribution by about $193,000.
Management said new tools are being rolled out across its practices to cut time spent on documentation and administrative work. It expects them to improve patient experience and clinic-level efficiency.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
Where the growth came from
Management said revenue grew at the Wisconsin and Atlanta clinics. It said Wisconsin joined the Progyny network in the first quarter, which widened access for patients with Progyny coverage.
The Indiana clinic, acquired in February, and the Birmingham clinic, acquired in late June, each added a full quarter of revenue.
Product revenue fell to $15,069 from $34,871. Sales to Indiana and Birmingham were eliminated once those clinics became consolidated subsidiaries.
INVO Fertility said it attended the American Society for Reproductive Medicine Scientific Congress Expo in Baltimore in October 2026. It said the meeting led to more potential acquisition opportunities.
Balance sheet and liquidity
Cash was $3.70 million at Sept. 30. Current liabilities were $4.46 million, down from $10.33 million at Dec. 31, 2025.
The balance sheet is cleaner than at year-end, but cash still trails near-term obligations.
INVO Fertility said assets rose $5.3 million and liabilities fell $5.5 million. Net equity reached $18.0 million, or $15.09 per share.
The company had 1,192,860 shares of common stock outstanding as of Nov. 13, 2026.
What's next
INVO Fertility will host a webcast on Monday, Nov. 16, 2026, at 11:00 a.m. Eastern Time to discuss third-quarter results and give a business update.
Clinic growth that continues without leaning so heavily on acquisitions would strengthen the case. Another quarter of negative companywide Adjusted EBITDA would leave the turnaround unfinished.
More from OptimistFi
- IVF stock: research and coverage of INVO Fertility
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
Sources
- SEC 8-K Exhibit 99.1 press release — Press release dated Nov. 16, 2026 with third-quarter 2026 results.
- SEC Form 8-K — Current report filed Nov. 16, 2026 containing the furnished press release.
Explore OptimistFi research on INVO Fertility, Inc.: https://optimistfi.com/stocks/IVF
Browse INVO Fertility, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the INVO Fertility, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
